These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1093 related items for PubMed ID: 10084271

  • 1. Intraocular pressure-lowering effects of latanoprost monotherapy versus latanoprost or pilocarpine in combination with timolol: a randomized, observer-masked multicenter study in patients with open-angle glaucoma. Italian Latanoprost Study Group.
    Bucci MG.
    J Glaucoma; 1999 Feb; 8(1):24-30. PubMed ID: 10084271
    [Abstract] [Full Text] [Related]

  • 2. Circadian intraocular pressure control with dorzolamide versus timolol maleate add-on treatments in primary open-angle glaucoma patients using latanoprost.
    Tamer C, Oksüz H.
    Ophthalmic Res; 2007 Feb; 39(1):24-31. PubMed ID: 17164574
    [Abstract] [Full Text] [Related]

  • 3. A study of replacement of timolol-pilocarpine with latanoprost in pseudoexfoliation glaucoma.
    Bojić L, Mandić Z, Novak-Laus K, Sonicki Z, Karelović D.
    Coll Antropol; 2003 Dec; 27(2):729-34. PubMed ID: 14746165
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of latanoprost versus pilocarpine/timolol maleate fixed combination in patients with primary open-angle glaucoma or ocular hypertension.
    Kałuzny J, Sobecki R, Czechowicz-Janicka K, Kecik D, Kałuzny BJ, Stewart JA, Stewart WC.
    Acta Ophthalmol; 2008 Dec; 86(8):860-5. PubMed ID: 18721251
    [Abstract] [Full Text] [Related]

  • 5. Using diurnal intraocular pressure fluctuation to assess the efficacy of fixed-combination latanoprost/timolol versus latanoprost or timolol monotherapy.
    Varma R, Hwang LJ, Grunden JW, Bean GW.
    Br J Ophthalmol; 2010 Jan; 94(1):80-4. PubMed ID: 19692375
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of the fixed combinations latanoprost/timolol versus dorzolamide/timolol in patients with elevated intraocular pressure.
    Shin DH, Feldman RM, Sheu WP, Fixed Combination Latanoprost/Timolol Study Group.
    Ophthalmology; 2004 Feb; 111(2):276-82. PubMed ID: 15019375
    [Abstract] [Full Text] [Related]

  • 7. Comparing diurnal and nocturnal effects of brinzolamide and timolol on intraocular pressure in patients receiving latanoprost monotherapy.
    Liu JH, Medeiros FA, Slight JR, Weinreb RN.
    Ophthalmology; 2009 Mar; 116(3):449-54. PubMed ID: 19157559
    [Abstract] [Full Text] [Related]

  • 8. A 12-month, randomized, double-masked study comparing latanoprost with timolol in pigmentary glaucoma.
    Mastropasqua L, Carpineto P, Ciancaglini M, Gallenga PE.
    Ophthalmology; 1999 Mar; 106(3):550-5. PubMed ID: 10080213
    [Abstract] [Full Text] [Related]

  • 9. A 6-week, double-masked, parallel-group study of the efficacy and safety of travoprost 0.004% compared with latanoprost 0:005%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension.
    Franks WA, Renard JP, Cunliffe IA, Rojanapongpun P.
    Clin Ther; 2006 Mar; 28(3):332-9. PubMed ID: 16750448
    [Abstract] [Full Text] [Related]

  • 10. Additive intraocular pressure reduction effect of fixed combination of maleate timolol 0.5%/dorzolamide 2% (Cosopt) on monotherapy with latanoprost (Xalatan) in patients with elevated intraocular pressure: a prospective, 4-week, open-label, randomized, controlled clinical trial.
    Hatanaka M, Reis A, Sano ME, Susanna R.
    J Glaucoma; 2010 Mar; 19(5):331-5. PubMed ID: 19730119
    [Abstract] [Full Text] [Related]

  • 11. Comparison of the effects of bimatoprost and a fixed combination of latanoprost and timolol on circadian intraocular pressure.
    Rossetti L, Karabatsas CH, Topouzis F, Vetrugno M, Centofanti M, Boehm A, Viswanathan A, Vorwerk C, Goldblum D.
    Ophthalmology; 2007 Dec; 114(12):2244-51. PubMed ID: 17459480
    [Abstract] [Full Text] [Related]

  • 12. The additive intraocular pressure-lowering effect of latanoprost 0.005% daily once and pilocarpine 2% t.i.d. in patients with open-angle glaucoma or ocular hypertension. a 6-month, randomized, multicenter study. German Latanoprost Study Group.
    Diestelhorst M.
    Graefes Arch Clin Exp Ophthalmol; 2000 May; 238(5):433-9. PubMed ID: 10901475
    [Abstract] [Full Text] [Related]

  • 13. Comparison of the intraocular pressure lowering effect of latanoprost and a fixed combination of timolol-pilocarpine eye drops in patients insufficiently controlled with beta adrenergic antagonists. French Latanoprost Study Group, and the Swedish Latanoprost Study Group.
    Nordmann JP, Söderström M, Rouland JF, Malecaze F.
    Br J Ophthalmol; 2000 Feb; 84(2):181-5. PubMed ID: 10655195
    [Abstract] [Full Text] [Related]

  • 14. A 12-week, randomized, double-masked, multicenter study of the fixed combination of latanoprost and timolol in the evening versus the individual components.
    Diestelhorst M, Larsson LI, European-Canadian Latanoprost Fixed Combination Study Group.
    Ophthalmology; 2006 Jan; 113(1):70-6. PubMed ID: 16263174
    [Abstract] [Full Text] [Related]

  • 15. Second-line therapy with dorzolamide/timolol or latanoprost/timolol fixed combination versus adding dorzolamide/timolol fixed combination to latanoprost monotherapy.
    Konstas AG, Mikropoulos D, Dimopoulos AT, Moumtzis G, Nelson LA, Stewart WC.
    Br J Ophthalmol; 2008 Nov; 92(11):1498-502. PubMed ID: 18703549
    [Abstract] [Full Text] [Related]

  • 16. Twenty-four-hour diurnal curve comparison of commercially available latanoprost 0.005% versus the timolol and dorzolamide fixed combination.
    Konstas AG, Papapanos P, Tersis I, Houliara D, Stewart WC.
    Ophthalmology; 2003 Jul; 110(7):1357-60. PubMed ID: 12867391
    [Abstract] [Full Text] [Related]

  • 17. Diurnal intraocular pressure reduction with latanoprost 0.005% compared to timolol maleate 0.5% as monotherapy in subjects with exfoliation glaucoma.
    Konstas AG, Mylopoulos N, Karabatsas CH, Kozobolis VP, Diafas S, Papapanos P, Georgiadis N, Stewart WC.
    Eye (Lond); 2004 Sep; 18(9):893-9. PubMed ID: 15002024
    [Abstract] [Full Text] [Related]

  • 18. [Timolol 0.5%/dorzolamide 2% fixed combination versus timolol 0.5%/pilocarpine 2% fixed combination in primary open-angle glaucoma or ocular hypertensive patients].
    Kałuzny JJ, Szaflik J, Czechowicz-Janicka K, Kałuzny J, Orzałkiewicz A, Zaleska-Zmijewska A, Krajewska M, Stewart JA, Leech JN, Stewart WC.
    Klin Oczna; 2004 Sep; 106(1-2 Suppl):241-2. PubMed ID: 15510513
    [Abstract] [Full Text] [Related]

  • 19. 24-Hour IOP control with once-daily bimatoprost, timolol gel-forming solution, or latanoprost: a 1-month, randomized, comparative clinical trial.
    Walters TR, DuBiner HB, Carpenter SP, Khan B, VanDenburgh AM, Bimatoprost Circadian IOP Study Group.
    Surv Ophthalmol; 2004 Mar; 49 Suppl 1():S26-35. PubMed ID: 15016559
    [Abstract] [Full Text] [Related]

  • 20. Effectiveness and safety of dorzolamide-timolol alone or combined with latanoprost in open-angle glaucoma or ocular hypertension.
    Lesk MR, Koulis T, Sampalis F, Sampalis JS, Bastien NR.
    Ann Pharmacother; 2008 Apr; 42(4):498-504. PubMed ID: 18364402
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 55.